INCY:NASDAQ
Incyte Corp
$126.01
arrow_upward
+1.29%(+1.61) 1D
$126.01
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 9, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INCY...
Open
$125.66
High
$127.72
Low
$123.57
Mkt. cap
25.54B
Avg. vol.
1.60M
Volume
0.00
P/E ratio
16.06
52-wk high
$132.58
52-wk low
$81.09
EPS
$7.85
Beta
0.77
Shares outstanding
202.70M
No. of employees
3K
Open
$125.66
High
$127.72
Low
$123.57
Mkt. cap
25.54B
Avg. vol.
1.60M
Volume
0.00
P/E ratio
16.06
52-wk high
$132.58
52-wk low
$81.09
EPS
$7.85
Beta
0.77
Shares outstanding
202.70M
No. of employees
3K
News stories
From web sources and news partners
TradingView
·
12 hours ago
INCY: Franchise expansion in hematology and GI oncology, with five late-stage assets, targets robust growth
News Corp
·
1 day ago
Incyte Corp. stock outperforms competitors despite losses on the day
Seeking Alpha
·
1 day ago
Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY)
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEOHervé Hoppenot
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteincyte.com